A Phase 1/2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

12 Nov 2024 According to a SpringWorks Therapeutics media release, data from 23 patients enrolled in the Phase 1 portion of the study this Phase 1/2 trial evaluating mirdametinib in pediatric and young adult patients with low-grade gliomas are being presented in an oral presentation at the 2024 SNO meeting. Phase 2 portion of the study is ongoing and recruiting patients.
04 Nov 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com